These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 21545354)

  • 1. Dry age-related macular degeneration: recent progress of therapeutic approaches.
    Kuno N; Fujii S
    Curr Mol Pharmacol; 2011 Nov; 4(3):196-232. PubMed ID: 21545354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anaphylatoxin Signaling in Retinal Pigment and Choroidal Endothelial Cells: Characteristics and Relevance to Age-Related Macular Degeneration.
    Rohrer B
    Adv Exp Med Biol; 2018; 1074():45-51. PubMed ID: 29721926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Developments in the Treatment of Wet Age-related Macular Degeneration.
    Papadopoulos Z
    Curr Med Sci; 2020 Oct; 40(5):851-857. PubMed ID: 32980899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New therapeutic targets in atrophic age-related macular degeneration.
    Petrukhin K
    Expert Opin Ther Targets; 2007 May; 11(5):625-39. PubMed ID: 17465722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AMD--the retinal disease with an unprecised etiopathogenesis: in search of effective therapeutics.
    Nowak JZ
    Acta Pol Pharm; 2014; 71(6):900-16. PubMed ID: 25745762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond AREDS Formulations, What Is Next for Intermediate Age-Related Macular Degeneration (iAMD) Treatment? Potential Benefits of Antioxidant and Anti-inflammatory Apocarotenoids as Neuroprotectors.
    Camelo S; Latil M; Veillet S; Dilda PJ; Lafont R
    Oxid Med Cell Longev; 2020; 2020():4984927. PubMed ID: 33520083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What determines the switch between atrophic and neovascular forms of age related macular degeneration? - the role of BMP4 induced senescence.
    Zhu D; Deng X; Xu J; Hinton DR
    Aging (Albany NY); 2009 Aug; 1(8):740-5. PubMed ID: 20157553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current therapeutic developments in atrophic age-related macular degeneration.
    Hanus J; Zhao F; Wang S
    Br J Ophthalmol; 2016 Jan; 100(1):122-7. PubMed ID: 26553922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retinal pigment epithelium and age-related macular degeneration: A review of major disease mechanisms.
    Somasundaran S; Constable IJ; Mellough CB; Carvalho LS
    Clin Exp Ophthalmol; 2020 Nov; 48(8):1043-1056. PubMed ID: 32710488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Effect of
    Ibuki M; Shoda C; Miwa Y; Ishida A; Tsubota K; Kurihara T
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31614647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Proinflammatory Function of Toll-Like Receptor 2 in the Retinal Pigment Epithelium as a Novel Target for Reducing Choroidal Neovascularization in Age-Related Macular Degeneration.
    Feng L; Ju M; Lee KYV; Mackey A; Evangelista M; Iwata D; Adamson P; Lashkari K; Foxton R; Shima D; Ng YS
    Am J Pathol; 2017 Oct; 187(10):2208-2221. PubMed ID: 28739342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hot Topics in Dry AMD.
    Narayanan R; Kuppermann BD
    Curr Pharm Des; 2017; 23(4):542-546. PubMed ID: 28003009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dry age-related macular degeneration like pathology in aged 5XFAD mice: Ultrastructure and microarray analysis.
    Park SW; Im S; Jun HO; Lee K; Park YJ; Kim JH; Park WJ; Lee YH; Kim JH
    Oncotarget; 2017 Jun; 8(25):40006-40018. PubMed ID: 28467791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Approaches with Intravitreal Injections in Geographic Atrophy Secondary to Age-Related Macular Degeneration: Current Drugs and Potential Molecules.
    Nebbioso M; Lambiase A; Cerini A; Limoli PG; La Cava M; Greco A
    Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30987401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.
    Becerra EM; Morescalchi F; Gandolfo F; Danzi P; Nascimbeni G; Arcidiacono B; Semeraro F
    Curr Drug Targets; 2011 Feb; 12(2):149-72. PubMed ID: 20887246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of age-related macular degeneration and therapeutic opportunities.
    van Lookeren Campagne M; LeCouter J; Yaspan BL; Ye W
    J Pathol; 2014 Jan; 232(2):151-64. PubMed ID: 24105633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exudative AMD subtypes and eligibility for treatment with ranibizumab.
    George S; Cooke C; Chakravarthy U
    Eye (Lond); 2010 Jul; 24(7):1247-51. PubMed ID: 20019764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The case for complement and inflammation in AMD: open questions.
    Karagianni N; Adamis AP
    Adv Exp Med Biol; 2010; 703():1-7. PubMed ID: 20711703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dry Age-Related Macular Degeneration Pharmacology.
    Wright CB; Ambati J
    Handb Exp Pharmacol; 2017; 242():321-336. PubMed ID: 27900609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exacerbation of choroidal and retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.
    Young M; Chui L; Fallah N; Or C; Merkur AB; Kirker AW; Albiani DA; Forooghian F
    Retina; 2014 Jul; 34(7):1308-15. PubMed ID: 24451923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.